Valneva: Funding, Investors & Team (Sep 2026)
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.
Valneva has raised $122M across 2 funding rounds on record, the most recent a Post-IPO Debt of $20.0M announced in Apr 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Valneva Company Profile and Key Stats
Latest funding round on record: Apr 2022.
Valneva Funding Rounds
Valneva raised $102M in a Post-IPO Equity announced in Nov 2021.
5 months later, a Post-IPO Debt of $20.0M was announced in Apr 2022.
Valneva Founders and Leadership Team
No contact details are on record for this team yet.
Valneva Funding Compared to Other Biotechnology Startups
Valneva's latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Valneva in Biotechnology and Saint-herblain
Companies Similar to Valneva
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Valneva Funding FAQs
What does Valneva do?
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.
How much funding has Valneva raised?
Valneva has raised $122M across 2 rounds on record. The most recent is a Post-IPO Debt of $20.0M announced in Apr 2022.
When did Valneva last raise funding?
Valneva's most recent funding round on record is a Post-IPO Debt of $20.0M, announced in Apr 2022.
Who is the CEO of Valneva?
Thomas Lingelbach is listed as CEO at Valneva.
Where is Valneva headquartered?
Valneva is based in Saint-herblain, Pays De La Loire, France.
How many employees does Valneva have?
Valneva is in the 501-1000 employee band.
How does Valneva's funding compare to other Biotechnology startups?
Valneva's latest round of $20.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Valneva Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Valneva is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.